A Tablet-Based Technology for Objective Exercise Monitoring in Vestibular Rehabilitation: Mixed Methods Study.

Only Ten participants from one tertiary balance center were studied, so the usability findings may not apply to a wider clinic population. There was no control group, no home-use period, and no measure of whether VestAid changed exercise adherence or clinical outcomes. Participants were not shown the objective gaze stabilization and head-speed compliance output, so the study did not test the feedback loop that VestAid is intended to support. The exercises were set at 80 beats per minute while seated, with 30-second trials and 1-minute rests, to help participants tolerate the session, so higher-dose or standing home exercise may not be represented. People with baseline dizziness above 5 out of 10, visual acuity worse than 20/40, loss of protective distal sensation, or less than 5 degrees of ankle dorsiflexion were excluded. The app's objective gaze and head-speed metrics were not compared with another standard, and the paper says their reliability and acceptable score ranges still need work.

One or more investigators has a financial interest in Intelligent Automation, a BlueHalo Company, which has rights to intellectual property being evaluated and developed as part of this study.

Do not conclude that VestAid improves vestibular rehabilitation outcomes or home exercise compliance. This was a small pilot usability study, and participants used the whole app, not isolated features such as the metronome or facial recognition, so the contribution of any single component cannot be separated.